A combination therapy for kras-Driven lung adenocarcinomas using lipophilic bisphosphonates and rapamycin

Science Translational Medicine

Volumn 6, Issue 263, 2014, Pages

  Xia, Yifeng ^a   Liu, Yi Liang ^b   Xie, Yonghua ^c   Zhu, Wei ^b   Guerra, Francisco ^b   Shen, Shen ^a   Yeddula, Narayana ^a   Fischer, Wolfgang ^d   Low, William ^d   Zhou, Xiaoying ^c   Zhang, Yonghui ^c,e,f   Oldfield, Eric ^b,g   Verma, Inder M ^a  

^a SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

^b UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^c Tsinghua University   (China)

^d SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

^e TSINGHUA UNIVERSITY   (China)

^f SICHUAN UNIVERSITY   (China)

^g UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; BPH 1222; CASPASE 3; CHLOROQUINE; EVEROLIMUS; GERANYLGERANYL PYROPHOSPHATE; GGTI 298; GUANINE NUCLEOTIDE BINDING PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; N [[5 [(2 AMINO 3 MERCAPTOPROPYL)AMINO][1,1' BIPHENYL] 2 YL]CARBONYL]METHIONINE METHYL ESTER; PROTEIN FARNESYLTRANSFERASE; PROTEIN P62; RAPAMYCIN; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; ENZYME ACTIVATION; FARNESYLATION; FEMALE; GENE MUTATION; LIPOPHILICITY; LUNG ADENOCARCINOMA; METABOLIC STRESS; MOUSE; NONHUMAN; ONCOGENE K RAS; OXIDATIVE STRESS; PRENYLATION; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN LOCALIZATION; PROTEIN PROCESSING; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; TUMOR VOLUME; UNFOLDED PROTEIN RESPONSE; X RAY CRYSTALLOGRAPHY; ADENOCARCINOMA; ANIMAL; COMBINATION DRUG THERAPY; LUNG NEOPLASMS; ONCOGENE RAS; PATHOLOGY;

ADENOCARCINOMA; ANIMALS; DIPHOSPHONATES; DRUG THERAPY, COMBINATION; GENES, RAS; LUNG NEOPLASMS; MICE; SIROLIMUS;

EID: 84911893167     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3010382     Document Type: Article

References (49)

1. J. Ansari, D. H. Palmer, D. W. Rea, S. A. Hussain, Role of tyrosine kinase inhibitors in lung cancer. Anticancer Agents Med. Chem. 9, 569-575 (2009)
2. H. West, R. Lilenbaum, D. Harpole, A. Wozniak, L. Sequist, Molecular analysis-based treatment strategies for the management of non-small cell lung cancer. J. Thorac. Oncol. 4, S1029-S1039 (2009)
3. E. L. Kwak, Y. J. Bang, D. R. Camidge, A. T. Shaw, B. Solomon, R. G. Maki, S. H. Ou, B. J. Dezube, P. A. Jänne, D. B. Costa,M. Varella-Garcia, W. H. Kim, T. J. Lynch, P. Fidias, H. Stubbs, J. A. Engelman, L. V. Sequist,W. Tan, L. Gandhi, M. Mino-Kenudson, G. C. Wei, S.M. Shreeve, M. J. Ratain, J. Settleman, J. G. Christensen, D. A. Haber, K. Wilner, R. Salgia, G. I. Shapiro, J. W. Clark, A. J. Iafrate, Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med. 363, 1693-1703 (2010)
4. E. Massarelli, M. Varella-Garcia, X. Tang, A. C. Xavier, N. C. Ozburn, D. D. Liu, B. N. Bekele, R. S. Herbst, I. I. Wistuba, KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin. Cancer Res. 13, 2890-2896 (2007)
5. J. L. Bos, ras oncogenes in human cancer: A review. Cancer Res. 49, 4682-4689 (1989)
6. J. M. Ostrem, U. Peters, M. L. Sos, J. A. Wells, K. M. Shokat, K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature 503, 548-551 (2013).
7. J. Downward, Targeting RAS signalling pathways in cancer therapy. Nat. Rev. Cancer 3, 11-22 (2003).
8. D. A. Chan, A. J. Giaccia, Harnessing synthetic lethal interactions in anticancer drug discovery. Nat. Rev. Drug Discov. 10, 351-364 (2011)
9. P. J. Casey, P. A. Solski, C. J. Der, J. E. Buss, p21ras is modified by a farnesyl isoprenoid. Proc. Natl. Acad. Sci. U.S.A. 86, 8323-8327 (1989)
10. J. H. Jackson, C. G. Cochrane, J. R. Bourne, P. A. Solski, J. E. Buss, C. J. Der, Farnesol modification of Kirsten-ras exon 4B protein is essential for transformation. Proc. Natl. Acad. Sci. U.S.A. 87, 3042-3046 (1990)
11. R. B. Lobell, C. A. Omer, M. T. Abrams, H. G. Bhimnathwala, M. J. Brucker, C. A. Buser, J. P. Davide, S. J. deSolms, C. J. Dinsmore, M. S. Ellis-Hutchings, A. M. Kral, D. Liu, W. C. Lumma, S. V. Machotka, E. Rands, T. M. Williams, S. L. Graham, G. D. Hartman, A. I. Oliff, D. C. Heimbrook, N. E. Kohl, Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models. Cancer Res. 61, 8758-8768 (2001)
12. G. J. Riely, J. Marks, W. Pao, KRAS mutations in non-small cell lung cancer. Proc. Am. Thorac. Soc. 6, 201-205 (2009)
13. G. Zimmermann, B. Papke, S. Ismail, N. Vartak, A. Chandra, M. Hoffmann, S. A. Hahn, G. Triola, A. Wittinghofer, P. I. Bastiaens, H. Waldmann, Small molecule inhibition of the KRAS-PDEd interaction impairs oncogenic KRAS signalling. Nature 497, 638-642 (2013).
14. M. Liu, A. K. Sjogren, C. Karlsson, M. X. Ibrahim, K. M. Andersson, F. J. Olofsson, A. M. Wahlstrom, M. Dalin, H. Yu, Z. Chen, S. H. Yang, S. G. Young, M. O. Bergo, Targeting the protein prenyltransferases efficiently reduces tumor development in mice with K-RAS-induced lung cancer. Proc. Natl. Acad. Sci. U.S.A. 107, 6471-6476 (2010)
15. A. K. Sjogren, K. M. Andersson, M. Liu, B. A. Cutts, C. Karlsson, A. M. Wahlstrom, M. Dalin, C. Weinbaum, P. J. Casey, A. Tarkowski, B. Swolin, S. G. Young, M. O. Bergo, GGTase-I deficiency reduces tumor formation and improves survival in mice with K-RAS-induced lung cancer. J. Clin. Invest. 117, 1294-1304 (2007)
16. S. F. Sousa, P. A. Fernandes, M. J. Ramos, Farnesyltransferase inhibitors: A detailed chemical view on an elusive biological problem. Curr. Med. Chem. 15, 1478-1492 (2008)
17. Y. Zhang, R. Cao, F. Yin, M. P. Hudock, R. T. Guo, K. Krysiak, S. Mukherjee, Y. G. Gao, H. Robinson, Y. Song, J. H. No, K. Bergan, A. Leon, L. Cass, A. Goddard, T. K. Chang, F. Y. Lin, E. Van Beek, S. Papapoulos, A. H. Wang, T. Kubo,M. Ochi, D. Mukkamala, E. Oldfield, Lipophilic bisphosphonatesas dual farnesyl/geranylgeranyl diphosphate synthase inhibitors: An X-ray and NMR investigation. J. Am. Chem. Soc. 131, 5153-5162 (2009)
18. T. Verfaillie, M. Salazar, G. Velasco, P. Agostinis, Linking ER stress to autophagy: Potential implications for cancer therapy. Int. J. Cell Biol. 2010, 930509 (2010)
19. B. M. Wasko, A. Dudakovic, R. J. Hohl, Bisphosphonates induce autophagy by depleting geranylgeranyl diphosphate. J. Pharmacol. Exp. Ther. 337, 540-546 (2011)
20. J. W. Wojtkowiak, K. M. Sane, M. Kleinman, B. F. Sloane, J. J. Reiners Jr., R. R. Mattingly, Aborted autophagy and nonapoptotic death induced by farnesyl transferase inhibitor and lovastatin. J. Pharmacol. Exp. Ther. 337, 65-74 (2011)
21. E. White, Deconvoluting the context-dependent role for autophagy in cancer. Nat. Rev. Cancer 12, 401-410 (2012)
22. J. D. Artz, A. K. Wernimont, J. E. Dunford, M. Schapira, A. Dong, Y. Zhao, J. Lew, R. G. Russell, F. H. Ebetino, U. Oppermann, R. Hui, Molecular characterization of a novel geranylgeranyl pyrophosphate synthase from Plasmodium parasites. J. Biol. Chem. 286, 3315-3322 (2011)
23. M.Goffinet, M. Thoulouzan, A. Pradines, I. Lajoie-Mazenc, C. Weinbaum, J. C. Faye, S. Séronie-Vivien, Zoledronic acid treatment impairs protein geranyl-geranylation for biological effects in prostatic cells. BMC Cancer 6, 60 (2006)
24. S. Mukherjee, C. Huang, F. Guerra, K. Wang, E. Oldfield, Thermodynamics of bisphosphonates binding to human bone: A two-site model. J. Am. Chem. Soc. 131, 8374-8375 (2009)
25. G. H. Fisher, S. L. Wellen, D. Klimstra, J. M. Lenczowski, J. W. Tichelaar, M. J. Lizak, J. A. Whitsett, A. Koretsky, H. E. Varmus, Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes. Genes Dev. 15, 3249-3262 (2001)
26. R. Haklai, M. G. Weisz, G. Elad, A. Paz, D. Marciano, Y. Egozi, G. Ben-Baruch, Y. Kloog,Dislodgment and accelerated degradation of Ras. Biochemistry 37, 1306-1314 (1998)
27. N. Berndt, A. D. Hamilton, S. M. Sebti, Targeting protein prenylation for cancer therapy. Nat. Rev. Cancer 11, 775-791 (2011)
28. N. Berndt, S. M. Sebti, Measurement of protein farnesylation and geranylgeranylation in vitro, in cultured cells and in biopsies, and the effects of prenyl transferase inhibitors. Nat. Protoc. 6, 1775-1791 (2011)
29. J. Luo, N. L. Solimini, S. J. Elledge, Principles of cancer therapy: Oncogene and non-oncogene addiction. Cell 136, 823-837 (2009)
30. C. Mörck, L. Olsen, C. Kurth, A. Persson, N. J. Storm, E. Svensson, J. O. Jansson, M. Hellqvist, A. Enejder, N. J. Faergeman, M. Pilon, Statins inhibit protein lipidation and induce the unfolded protein response in the non-sterol producing nematode Caenorhabditis elegans. Proc. Natl. Acad. Sci. U.S.A. 106, 18285-18290 (2009)
31. J. C. Chen, M. L. Wu, K. C. Huang, W. W. Lin, HMG-CoA reductase inhibitors activate the unfolded protein response and induce cytoprotective GRP78 expression. Cardiovasc. Res. 80, 138-150 (2008)
32. J. Y. Guo, H. Y. Chen, R. Mathew, J. Fan, A. M. Strohecker, G. Karsli-Uzunbas, J. J. Kamphorst, G. Chen, J. M. Lemons, V. Karantza, H. A. Coller, R. S. Dipaola, C. Gelinas, J. D. Rabinowitz, E. White, Activated Ras requires autophagy to maintain oxidative metabolism and tumorigenesis. Genes Dev. 25, 460-470 (2011)
33. S. Yang, X. Wang, G. Contino, M. Liesa, E. Sahin, H. Ying, A. Bause, Y. Li, J. M. Stommel, G. Dell'antonio, J. Mautner, G. Tonon, M. Haigis, O. S. Shirihai, C. Doglioni, N. Bardeesy, A. C. Kimmelman, Pancreatic cancers require autophagy for tumor growth. Genes Dev. 25, 717-729 (2011)
34. F. Janku, D. J. McConkey, D. S. Hong, R. Kurzrock, Autophagy as a target for anticancer therapy. Nat. Rev. Clin. Oncol. 8, 528-539 (2011)
35. M. T. Rosenfeldt, J. O'Prey, J. P. Morton, C. Nixon, G. MacKay, A. Mrowinska, A. Au, T. S. Rai, L. Zheng, R. Ridgway, P. D. Adams, K. I. Anderson, E. Gottlieb, O. J. Sansom, K. M. Ryan, p53 status determines the role of autophagy in pancreatic tumour development. Nature 504, 296-300 (2013)
36. A. Duran, J. F. Linares, A. S. Galvez, K. Wikenheiser, J. M. Flores, M. T. Diaz-Meco, J. Moscat, The signaling adaptor p62 is an important NF-kB mediator in tumorigenesis. Cancer Cell 13, 343-354 (2008)
37. Y. Xia, N. Yeddula, M. Leblanc, E. Ke, Y. Zhang, E. Oldfield, R. J. Shaw, I. M. Verma, Reduced cell proliferation by IKK2 depletion in amouse lung-cancermodel. Nat. Cell Biol. 14, 257-265 (2012)
38. G. Hatzivassiliou, J. R. Haling, H. Chen, K. Song, S. Price, R. Heald, J. F. Hewitt, M. Zak, A. Peck, C. Orr, M. Merchant, K. P. Hoeflich, J. Chan, S. M. Luoh, D. J. Anderson, M. J. Ludlam, C. Wiesmann, M. Ultsch, L. S. Friedman, S. Malek, M. Belvin, Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers. Nature 501, 232-236 (2013)
39. G. Moriceau, B. Ory, L. Mitrofan, C. Riganti, F. Blanchard, R. Brion, C. Charrier, S. Battaglia, P. Pilet, M. G. Denis, L. D. Shultz, J. Mönkkönen, F. Rédini, D. Heymann, Zoledronic acid potentiates mTOR inhibition and abolishes the resistance of osteosarcoma cells to RAD001 (Everolimus): Pivotal role of the prenylation process. Cancer Res. 70, 10329-10339 (2010).
40. M. Gnant, B. Mlineritsch, W. Schippinger, G. Luschin-Ebengreuth, S. Pöstlberger, C. Menzel, R. Jakesz, M. Seifert, M. Hubalek, V. Bjelic-Radisic, H. Samonigg, C. Tausch, H. Eidtmann, G. Steger, W. Kwasny, P. Dubsky, M. Fridrik, F. Fitzal, M. Stierer, E. Rücklinger, R. Greil; ABCSG-12 Trial Investigators, C. Marth, Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N. Engl. J. Med. 360, 679-691 (2009).
41. J. H. Lin, Bisphosphonates: A review of their pharmacokinetic properties. Bone 18, 75-85 (1996).
42. H. M. Weiss, U. Pfaar, A. Schweitzer, H. Wiegand, A. Skerjanec, H. Schran, Biodistribution and plasma protein binding of zoledronic acid. Drug Metab. Dispos. 36, 2043-2049 (2008).
43. Y. Chien, S. Kim, R. Bumeister, Y. M. Loo, S. W. Kwon, C. L. Johnson, M. G. Balakireva, Y. Romeo, L. Kopelovich, M. Gale Jr., C. Yeaman, J. H. Camonis, Y. Zhao, M. A. White, RalB GTPasemediated activation of the IkB family kinase TBK1 couples innate immune signaling to tumor cell survival. Cell 127, 157-170 (2006).
44. S. C. Falsetti, D. A. Wang, H. Peng, D. Carrico, A. D. Cox, C. J. Der, A. D. Hamilton, S. M. Sebti, Geranylgeranyltransferase I inhibitors target RalB to inhibit anchorage-dependent growth and induce apoptosis and RalA to inhibit anchorage-independent growth. Mol. Cell. Biol. 27, 8003-8014 (2007).
45. J. L. Kissil,M. J.Walmsley, L. Hanlon, K.M.Haigis, C. F. Bender Kim, A. Sweet-Cordero, M. S. Eckman, D. A. Tuveson, A. J. Capobianco, V. L. Tybulewicz, T. Jacks, Requirement for Rac1 in a K-ras-induced lung cancer in the mouse. Cancer Res. 67, 8089-8094 (2007).
46. Y. Zhang, W. Zhu, Y. L. Liu, H. Wang, K. Wang, K. Li, J. H. No, L. Ayong, A. Gulati, R. Pang, L. Freitas-Junior, C. T. Morita, E. Oldfield, Chemo-immunotherapeutic antimalarials targeting isoprenoid biosynthesis. ACS Med. Chem. Lett. 4, 423-427 (2013).
47. P. Emsley, B. Lohkamp, W. G. Scott, K. Cowtan, Features and development of Coot. Acta Crystallogr. D Biol. Crystallogr. 66, 486-501 (2010).
48. W. Minor, M. Cymborowski, Z. Otwinowski, M. Chruszcz, HKL-3000: The integration of data reduction and structure solution-From diffraction images to an initial model in minutes. Acta Crystallogr. D Biol. Crystallogr. 62, 859-866 (2006).
49. M. D. Winn, C. C. Ballard, K. D. Cowtan, E. J. Dodson, P. Emsley, P. R. Evans, R. M. Keegan,E. B. Krissinel, A. G. Leslie, A. McCoy, S. J. McNicholas, G. N. Murshudov, N. S. Pannu, E. A. Potterton, H. R. Powell, R. J. Read, A. Vagin, K. S. Wilson, Overview of the CCP4 suite and current developments. Acta Crystallogr. D Biol. Crystallogr. 67, 235-242 (2011).